The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Leqvio, in combination with maximally tolerated statin therapy, is administered as an initial single subcutaneous injection, a second dose at 3 months, and continued treatment once every 6 months.

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C) 1 4 out of 5 ...

With two maintenance doses a year, Leqvio is the first and only FDA- approved small interfering RNA therapy for LDL-C reduction 1 Leqvio provides effective and sustained LDL-C reduction of up to ...

The U.S. delay for Leqvio has weighed on Novartis's sales growth, which was already being crimped by the pandemic. And a big study of the drug in Britain has been pushed back as COVID-19 disrupted ...

Leqvio (inclisiran) and Repatha (evelocumab) are prescription injectable medications used to treat high cholesterol. They specifically target low-density lipoprotein cholesterol (LDL-C), or "bad ...

Leqvio lowers cholesterol by preventing your liver from making PCSK9. If you use Repatha or Praluent, but it’s not lowering your cholesterol enough, your doctor may have you stop your current ...

Leqvio is a liquid that is injected under the skin by a health care professional in a health care setting. Each injection can be given into the thigh, stomach, or outer area of the upper arm.